{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:32:54Z","timestamp":1768091574671,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970689"],"award-info":[{"award-number":["81970689"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20181116"],"award-info":[{"award-number":["BK20181116"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.eprac.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T10:12:19Z","timestamp":1643796739000},"page":"515-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Decreased Serum Wnt Antagonist Levels in Patients With Active Acromegaly"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0410-2533","authenticated-orcid":false,"given":"Huan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengsi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2022.01.011_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.eprac.2022.01.011_bib2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.01.011_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/er.2018-00005","article-title":"Pituitary diseases and bone","volume":"39","author":"Mazziotti","year":"2018","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.eprac.2022.01.011_bib4","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EJE-19-0184","article-title":"Management of endocrine disease: bone disorders associated with acromegaly: mechanisms and treatment","volume":"181","author":"Mazziotti","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.01.011_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.eprac.2022.01.011_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1530\/EJE-20-0415","article-title":"Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study","volume":"183","author":"Pelsma","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2022.01.011_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrendo.2013.154","article-title":"Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches","volume":"9","author":"Canalis","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.01.011_bib8","doi-asserted-by":"crossref","first-page":"a015081","DOI":"10.1101\/cshperspect.a015081","article-title":"Secreted and transmembrane Wnt inhibitors and activators","volume":"5","author":"Cruciat","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"10.1016\/j.eprac.2022.01.011_bib9","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/rheumatology\/kev410","article-title":"Novel biological markers of bone: from bone metabolism to bone physiology","volume":"55","author":"Chapurlat","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"10.1016\/j.eprac.2022.01.011_bib10","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.01.011_bib11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1210\/jc.2014-2912","article-title":"Increased serum and bone matrix levels of the secreted Wnt antagonist DKK-1 in patients with growth hormone deficiency in response to growth hormone treatment","volume":"100","author":"Ueland","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.01.011_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12020-021-02751-9","article-title":"Prevalence of vertebral fractures and serum sclerostin levels in acromegaly","volume":"73","author":"Uygur","year":"2021","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.eprac.2022.01.011_bib13","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1210\/clinem\/dgab260","article-title":"Impaired bone microarchitecture in premenopausal women with acromegaly: the possible role of Wnt signaling","volume":"106","author":"Silva","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.01.011_bib14","doi-asserted-by":"crossref","first-page":"dgz254","DOI":"10.1210\/clinem\/dgz254","article-title":"Increased serum sclerostin levels in patients with active acromegaly","volume":"105","author":"Pekkolay","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.01.011_bib15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12020-016-0945-2","article-title":"Epicardial fat is a negative predictor of spine volumetric bone mineral density and trabecular bone score in acromegaly","volume":"53","author":"Valassi","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2022.01.011_bib16","first-page":"S182","article-title":"Bone turnover markers and serum sclerostin levels in patients with acromegaly","volume":"27","author":"Tsoriev","year":"2016","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.eprac.2022.01.011_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01623829","article-title":"Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption","volume":"3","author":"Eastell","year":"1993","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2022.01.011_bib18","doi-asserted-by":"crossref","first-page":"115115","DOI":"10.1016\/j.bone.2019.115115","article-title":"Increases in PYY and uncoupling of bone turnover are associated with loss of bone mass after gastric bypass surgery","volume":"131","author":"Kim","year":"2020","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.eprac.2022.01.011_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/EC-18-0482","article-title":"Circulating miR-103a-3p and miR-660-5p are associated with bone parameters in patients with controlled acromegaly","volume":"8","author":"Valassi","year":"2019","journal-title":"Endocr Connect"},{"issue":"12","key":"10.1016\/j.eprac.2022.01.011_bib20","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1242\/jcs.02975","article-title":"The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis","volume":"119","author":"Christodoulides","year":"2006","journal-title":"J\u00a0Cell Sci"},{"issue":"2","key":"10.1016\/j.eprac.2022.01.011_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2141.2009.07587.x","article-title":"Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma","volume":"145","author":"Voorzanger-Rousselot","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.eprac.2022.01.011_bib22","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1002\/dvdy.20939","article-title":"Cultured endothelial cells display endogenous activation of the canonical Wnt signaling pathway and express multiple ligands, receptors, and secreted modulators of Wnt signaling","volume":"235","author":"Goodwin","year":"2006","journal-title":"Dev Dyn"},{"issue":"9","key":"10.1016\/j.eprac.2022.01.011_bib23","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in\u00a0vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"10.1016\/j.eprac.2022.01.011_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00223-016-0160-4","article-title":"Decreased plasma levels of sclerostin but not Dickkopf-1 are associated with an increased prevalence of osteoporotic fracture and lower bone mineral density in postmenopausal Korean women","volume":"99","author":"Lim","year":"2016","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.01.011_bib25","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1210\/jc.2013-2244","article-title":"Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta","volume":"99","author":"Kocijan","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.01.011_bib26","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1210\/jc.2016-3693","article-title":"Calcium and bone turnover markers in acromegaly: a prospective, controlled study","volume":"102","author":"Constantin","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.01.011_bib27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1210\/jc.2014-2937","article-title":"Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis","volume":"100","author":"Mazziotti","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22000350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22000350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:12:10Z","timestamp":1761516730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22000350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1530891X22000350"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.01.011","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased Serum Wnt Antagonist Levels in Patients With Active Acromegaly","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}